1.   British drugmaker Glaxo-Wellcome is already testing a different neuraminidase inhibitor that is delivered by an inhaler because the molecule cannot be taken orally.

2.   Other researchers in Australia previously developed a neuraminidase inhibitor designed to be inhaled.

3.   The drugs, called neuraminidase inhibitors, have a unique action which does not stop infection but prevents the virus spreading within the body.

4.   The new drugs, called neuraminidase inhibitors, attack both the A and B strains by isolating the virus and keeping it from reproducing.

5.   Glaxo officials said the drug is the first of a new class, called neuraminidase inhibitors, that attacks both type A and type B flu strains.

6.   It is the first in a new generation of flu treatments known as neuraminidase inhibitors.

7.   Relenza will be the first of a new class of flu medicines known as neuraminidase inhibitors to reach the market.